As the 2026 midterm elections approach, pharmacies face significant policy developments that could reshape drug pricing, reimbursement, and patient access to medications. In an FAQ with Drug Topics, A.J. Barbarito examines the regulatory and legislative issues pharmacists should monitor, including pharmacy benefit manager (PBM) reform, Most-Favored-Nation (MFN) drug pricing policies, Medicare drug price negotiations, and changes to Affordable Care Act (ACA) subsidies. While the election outcome could influence legislative priorities, bipartisan support for PBM reform suggests continued scrutiny of pharmacy reimbursement practices and contractual transparency.
“Regardless of which party controls Congress after the midterms, pharmacists should prepare for continued pressure on drug pricing, PBM practices, and health care affordability.”
For pharmacies, these policy developments carry practical implications that extend beyond Washington. Changes to drug pricing and reimbursement could affect pharmacy profitability, while evolving PBM regulations may alter contractual obligations and reimbursement practices. At the same time, affordability pressures could influence patients’ ability to access and maintain their medications. With additional federal regulatory action under consideration, pharmacies should closely evaluate how these developments may affect their operations, financial stability, and long-term planning.
Part 1 of Drug Topics’ pre-election series: FAQ: How the 2026 Midterms Could Reshape Pharmacy Policy
Senior Associate
